Journal: Molecular medicine reports

Article Title: Quercetin protects RAW264.7 macrophages from glucosamine-induced apoptosis and lipid accumulation via the endoplasmic reticulum stress pathway.

doi: 10.3892/mmr.2015.4340

Figure Lengend Snippet: Figure 3. Effects of quercetin on apoptosis‑ and ER stress‑associated proteins in glucosamine‑induced RAW264.7 macrophages. (A) Expression levels of phospho‑JNK and JNK were measured using western blotting. (B) Expression levels of CHOP and cleaved‑caspase‑12 were measured using western blotting and normalized to the levels of β‑actin. (C) Expression levels of GRP78 and ATF6α (90 KDa) were measured using western blotting and normalized to the levels of β‑actin. Data are presented as the mean ± standard deviations of at least three independent experiments. aP<0.01, vs. vehicle‑treated control; bP<0.01, vs. glucosamine treatment; cP<0.01, vs. quercetin (20 µM) treatment. ER, endoplasmic reticulum; JNK, c‑Jun N‑terminal kinase; phospho‑JNK, phosphorylated‑JNK; CHOP, C/EBP homologous protein; GRP78, glucose regulated protein 78; ATF6, activating transcriptional factor 6.

Article Snippet: Polyclonal antibodies against glucose regulated protein 78 (GRP78; cat. no. 3183), C/EBP homologous protein (CHOP; cat. no. 2895) and β-actin (cat. no. 4970) were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA); those against c-Jun N-terminal kinase (JNK) (sc-7345), phosphorylated (p-)JNK (cat. no. sc-6254) and caspase-12 (cat. no. sc-5627) were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, US), and antibody against activating transcriptional factor 6α (cat. no. ATF6α; full length) was obtained from Acris Antibodies GmbH (Herford, Germany).

Techniques: Expressing, Western Blot, Control

Journal: Medicine

Article Title: Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 “STARD Compliant”

doi: 10.1097/MD.0000000000001972

Figure Lengend Snippet: ATF6α high p-p38 low signature predicts shorter time to recurrence after surgery. A, Four representative immunostaining of ATF6α and p-p38 showing differential expression pattern. B, Kaplan–Meier analysis for time to recurrence after surgery of patients showing ATF6α high p-p38 low expression (green line) versus low-risk patients (blue line). C, Kaplan–Meier analysis for overall survival of patients with ATF6α high p-p38 low (green line) versus low-risk patients (blue line).

Article Snippet: Biopsies were stained for 20 minutes with a 1:750 dilution of ATF6α antibody (AP08853PU-N, Acris Antibodies) and 1:150 of p-p38 (ab38238, Abcam), followed by incubation with the appropriate anti-Ig horseradish peroxidase-conjugated polymer (EnVision, Dako) to detect antigen-antibody.

Techniques: Immunostaining, Quantitative Proteomics, Expressing

Journal: Medicine

Article Title: Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 “STARD Compliant”

doi: 10.1097/MD.0000000000001972

Figure Lengend Snippet: Proposed model by which ATF6α and p-p38 could modulate pancreatic cancer survival. ER = endoplasmic reticulum.

Article Snippet: Biopsies were stained for 20 minutes with a 1:750 dilution of ATF6α antibody (AP08853PU-N, Acris Antibodies) and 1:150 of p-p38 (ab38238, Abcam), followed by incubation with the appropriate anti-Ig horseradish peroxidase-conjugated polymer (EnVision, Dako) to detect antigen-antibody.

Techniques: